Takeda Pharmaceutical Company Limited

Michiyo Mochizuki

Kazuyoshi Aso

Masakuni Kori

Masato Yoshikawa

Shinji Nakamura

Masaki Seto

Toshihiro Imaeda

Masashi Toyofuku

Eiji Honda

Yasutomi Asano

Akito Shibuya

Zenyu Shiokawa

Osamu Ujikawa

Yusuke Tominari

Morihisa Saitoh

Tomohiro Seki

Kosuke Hidaka

Yoshihisa Nakada

Yasuo Nakagawa

Yayoi Nakayama

Katsumi Kobayashi

Taisuke Kato

Tsuneo Oda

Albert Charles Gyorkos

Takuto Kojima

Christopher Peter Corrette

Yusuke Sasaki

Takafumi Takai

Paul D Greenspan

Brian Scott Freeze

Yasufumi Wada

Taisuke Tawaraishi

Suk Young Cho

Shumpei Murata

Christopher Stephen Siedem

Kazuyuki Tokumaru

Atsutoshi Okabe

Steven Armen Boyd

Kevin Ronald Condroski

Yasutaka Hoashi

Masanori Okaniwa

Scott Alan Pratt

Timothy Mark Turner

Yayoi Yoshitomi

The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

Methods of making a cyclic dinucleotide

Antibody-drug conjugates comprising a cyclic dinucleotide

Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (&#x3b1;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.

Heterocyclic compound and use thereof

Cyclic dinucleotide

There is provided a compound of the formula (I'): wherein X is a nitrogen or CRx, Rx is a hydrogen, etc., Ris an optionally substituted hydrocarbon group, etc., Ris an optionally substituted hydrocarbon group, etc., ring A is 5- to -8-membered heterocyclic ring, etc., and each of Y, Yand Yis an optionally substituted carbon or a nitrogen, etc.; or 'a salt thereof or a prodrug thereof, which have CRF receptor antagonistic activity and use thereof. 

Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them

There is provided a compound of the formula (I'): wherein x is a nitrogen or CRx, Rx is a hydrogen, etc., Ris an optionally substituted hydrocarbon group, etc., Ris an optionally substituted hydrocarbon group, etc., ring A is 5- to 8-membered heterocyclic ring, etc., and each of Y, Yand Yis an optionally substituted carbon or a nitrogen, etc.; or a salt thereof or a prodrug thereof, which have CRF receptor antagonistic activity and use thereof.

Tricyclic compounds and use thereof

There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein Ris an optionally substituted hydrocarbyl, an optionally substituted C-linked heterocyclic group, an optionally substituted N-linked heteroaryl group, a cyano or an acyl; Ris an optionally substituted cyclic hydrocarbyl or an optionally substituted heterocyclic group; X is oxygen, sulfur or &#x2014;NR&#x2014; (wherein Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl); Y, Yand Yare each an optionally substituted carbon or a nitrogen, provided that one or less of Y, Yand Yis nitrogen; and Z is a bond, &#x2014;CO&#x2014;, oxygen, sulfur, &#x2014;SO&#x2014;, &#x2014;SO&#x2014;, &#x2014;NR&#x2014;, &#x2014;NR-alk-, &#x2014;CONR&#x2014; or &#x2014;NRCO&#x2014; (wherein alk is an optionally substituted Calkylene and Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl); or a salt thereof or a prodrug thereof.

Fused heterocyclic compounds

There is provided a compound of the formula: wherein Ris an optionally substituted hydrocarbyl, a substituted amino, etc.; Ris an aromatic group substituted with one or two substituents at the positions adjacent to the position bonded to Z, and said aromatic group may have additional substituent(s); X is &#x2014;NR&#x2014; wherein Ris a hydrogen, an optionally substituted hydrocarbyl or an acyl, or sulfur; Y, Yand Yare an optionally substituted methine or a nitrogen, etc.; and Z is an optionally substituted methylene, provided that carbonyl is excluded; or a salt thereof or a prodrug thereof, which have CRF receptor antagonist activity and use thereof.

There is provided a CRF receptor antagonist comprising a compound of the formula (I):A-W&#x2014;Ar&#x2003;&#x2003;(I) 

Cyclic compounds

Growing community of inventors

Osaka, Japan

Michiyo Mochizuki